Back to results
US 9,308,200 B2Granted
Dry powder formulation comprising a phosphodiesterase inhibitor
AssigneeChiesi Farmaceutici S.p.A.
InventorsDaniela Cocconi, Francesca Schiaretti, Roberto Bilzi
Life of this patent
Estimating the term…
Abstract
Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.
Claims20
An inhalable dry powder formulation, comprising:
- (a) micronized particles of the (−) enantiomer of active ingredient 3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
- and
- (b) particles of a carrier comprising a mixture of coarse particles comprised of alpha-lactose monohydrate having a mass diameter of 150 to 400 microns, finely divided particles comprised of alpha-lactose monohydrate having a mass median diameter (MMD) equal to or less than 10 microns, and magnesium stearate.
Dependencies are inferred from the claim text.